OVID Stock Summary and Trading Ideas (Ovid Therapeutics | NASDAQ:OVID)

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Ovid Therapeutics trades on the NASDAQ stock market under the symbol OVID.

As of April 15, 2026, OVID stock price declined to $2.78 with 2,626,502 million shares trading.

OVID has a beta of 1.35, meaning it tends to be more sensitive to market movements. OVID has a correlation of 0.03 to the broad based SPY ETF.

OVID has a market cap of $419.86 million. This is considered a Small Cap stock.

Last quarter Ovid Therapeutics reported $718,000 in Revenue and $.06 earnings per share. This beat revenue expectation by $584,440 and exceeded earnings estimates by $.16.

In the last 3 years, OVID traded as high as $4.14 and as low as $.24.

The top ETF exchange traded funds that OVID belongs to (by Net Assets): VTI, VXF, BSVO, PRFZ, QQQS.

OVID has outperformed the market in the last year with a price return of +868.6% while the SPY ETF gained +30.8%. OVID has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +68.5% and +25.2%, respectively, while the SPY returned +1.3% and +7.3%, respectively.

OVID support price is $2.79 and resistance is $3.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OVID shares will trade within this expected range on the day.